| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate |
2017-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107362365-B |
| titleOfInvention |
Application of GPR31 inhibitor in pharmacy |
| abstract |
Experimental research shows that the expression level of GPR31 protein is gradually increased along with the prolongation of tissue ischemia time, and a positive correlation exists between the expression level and the severity of tissue ischemia-reperfusion injury. Overexpression of GPR31 can increase activity of liver cells, cardiac muscle cells and kidney cells caused by H/R treatment. In addition, a decrease in GPR31 expression in hepatocytes may inhibit cellular lipid deposition caused by palmitate and oleate stimulation. Overexpression of GPR31 in cardiomyocytes aggravates cardiac hypertrophy due to angiotensin ii. Therefore, GPR31 inhibitors are useful for the preparation of medicaments for the treatment of diseases associated with ischemia reperfusion injury; myocardial hypertrophy and related diseases; metabolic disorders of the liver. |
| priorityDate |
2017-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |